A new study has been published Mar 06 2018, in the Peer-Reviewed Medical Journal called Journal of the American Medical Association (or JAMA). The Study found that PSA test screening did not achieve its aim of diagnosing fast-growing cancers in time to treat them and prevent Deaths.
Video is courtesy of the University of Bristol YouTube Channel
Title: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial
Author: Martin, Richard M.; Donovan, Jenny L.
Publisher: American Medical Association
Date: Mar 6, 2018
There were men who were tested and the PSA Test found that they had a High PSA. Of those who agreed to further treatment during the study, some men were seriously harmed by treatment. There were 8 deaths in the screening group related to either the biopsy or prostate cancer treatment and 7 in the control group.
Click on this Link to the study published In JAMA on on Mar 06 2018 and titled “Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer MortalityThe CAP Randomized Clinical Trial“.
Posted by Vincent Banial
Chemotherapy can be an effective treatment for Hodgkin’s disease (HD) – a type of lymphoma, which is a blood cancer. Chemotherapy can also be an effective form of treatment for Testicular Cancer.
What about other Cancers?
The following is taken from the abstract of that research Study :
“The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
The conclusion as found in the abstract was:
“it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.”.
Found a link using a web search. The link is below ( you have to copy and paste the URL if you wish to visit their site – as you would from a web search):
Basically that is supposed to be a PDF of the results from that study published on Dec 2004 in Clinical Oncology. It lists over twenty different Cancers and the percentage increases in 5 year survival rates for those patients who received Chemotherapy treatment for said Cancer.
Clinical Oncology had also published another research study in November 2004. You can view an abstract at nature.com by clicking on this line.
The following was the conclusion of the Nov 2004 published in Nov 2004:
“Adjuvant chemotherapy after potentially curative surgery can improve 5-year survival by 4% in patients with early-stage non-small-cell lung cancer (NSCLC, stages IB–IIIA).”.
So after surgery, Chemotherapy may increase the 5 year survival rate in about 4% of the patients. Yes, only 4%.
Using the above quoted studies and being overly generous, in my opinion it may seem that Chemotherapy does not increase the 5 year Survival Rate for about 85% of patients with many forms of Cancer. The exception is that yes it may be a form of effective treatment for Hodgkin’s Disease and for the treatment of Testicular Cancer.
With some Cancers the study chart (see the link to the PDF above) shows Chemotherapy to have zero effect on 5 years Survival Rate.
That leaves the question: Why is Chemotherapy being given to Cancer patients?
Disclaimer: The above is posted for information purposes only. I am not giving Medical Advice. If you have a medical issue please consult with your Licensed Medical Doctor, Specialist or other Medical Professional.
Something which has apparently been known in Cancer Research circles, has been formally announced to the public.
“Cannabis has been shown to kill cancer cells in the laboratory” posted by the National Cancer Institue at cancer.gov
Photo courtesy of the United States Fish and Wildlife Service
The info below is from the website of the National Cancer Institute (https://www.cancer.gov)
Cannabis and Cannabinoids (PDQ®)–Patient Version
- Questions and Answers About Cannabis
- Current Clinical Trials
- About This PDQ Summary
- General CAM Information
- Evaluation of CAM Therapies
- Questions to Ask Your Health Care Provider About CAM
- To Learn More About CAM
- View All Sections
- Cannabis , also known as marijuana, is a plant grown in many parts of the world which produces a resin containing compounds called cannabinoids. Some cannabinoids are psychoactive (acting on the brain and changing mood or consciousness) (see Question 1).
- The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3).
- By federal law, the possession of Cannabis is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana (see Question 1).
- In the United States, Cannabis is a controlled substance requiring special licensing for its use (see Question 1 and Question 3).
- Cannabinoids are active chemicals in Cannabis that cause drug -like effects throughout the body, including the central nervous system and the immune system (see Question 2).
- The main active cannabinoid in Cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC (see Question 2).
- Cannabinoids can be taken by mouth, inhaled, or sprayed under the tongue (see Question 5).
- Cannabis and cannabinoids have been studied in the laboratory and the clinic for relief of pain, nausea and vomiting, anxiety, and loss of appetite (see Question 6 and Question 7).
- Cannabis and cannabinoids may have benefits in treating the symptoms of cancer or the side effects of cancer therapies. There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited (see Question 7).
- Two cannabinoids (dronabinol and nabilone) are drugs approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of chemotherapy -related nausea and vomiting (see Question 7 and Question 10).
- Cannabis has been shown to kill cancer cells in the laboratory (see Question 6).
- At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy (see Question 7).
- Cannabis is not approved by the FDA for use as a cancer treatment (see Question 9).
******* end of post from cancer.gov *******
The following are additional links with info related to Cannabis and THC being able to kill Cancer Cells:
Antineoplastic Activity of Cannabinoids
Cannabinoid Receptor Ligands Mediate Growth Inhibition & Cell Death In Mantle Cell Lymphoma
Δ9-Tetrahydrocannabinol Induces Apoptosis in Human Prostate PC-3 Cells via a Receptor-Independent Mechanism
Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma
Photo of Cannabis plants courtesy of A7nubis and commons.wikimedia.org
Note from Vince: This is am extremely important change as the Cannabis grown by NIDA is an uncommon variety and apparently low in THC. The FDA could approve a Medical Study of the use of high THC Cannabis in the treatment of Cancer, but NIDA always had the final word. If they approved a medical study (their usual common response was “No”) the study had to use the NIDA supplied Cannabis variety.
WASHINGTON, D.C. — Today, the Drug Enforcement Administration (DEA) announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana. Since 1968, the University of Mississippi, under contract to the National Institute on Drug Abuse (NIDA), has maintained the only facility in the United States with federal permission to grow marijuana for research.
“It’s a complete and total end of the NIDA monopoly! There has been no production monopoly on any other Schedule I substance, like MDMA or LSD—only the cannabis plant. Licensing non-government cannabis producers, and thereby creating a path to FDA approval, will finally facilitate the removal of marijuana from Schedule I, and ultimately allow patients to receive insurance coverage for medical marijuana,” said Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).
MAPS has been working to eliminate this cannabis research blockade since 1999. NIDA’s marijuana is eligible for research, but cannot be sold as a prescription medicine, making it unacceptable to the Food and Drug Administration (FDA) for use in future Phase 3 studies. Ending the monopoly finally allows for a pathway to FDA approval for marijuana, which would thereby trigger rescheduling.
In 2001, MAPS partnered with University of Massachusetts-Amherst Professor Lyle Craker, Ph.D., to apply for a DEA license and end the monopoly. In 2007, after years of bureaucratic delays and lengthy legal hearings, a DEA Administrative Law Judge (ALJ) recommended that it would be in the public’s interest to grant Craker the license. In 2009, after almost two more years of delays and less than a week before the inauguration of President Obama, former DEA Administrator Michelle Leonhart rejected the ALJ recommendation. In 2011, Craker sued the DEA in the U.S. First Circuit Court of Appeals. In its 2013 decision, the Court uncritically accepted the DEA’s arguments that NIDA’s monopoly provided “an adequate supply produced under adequately competitive conditions.”
Since the 2013 decision, Craker’s argument that NIDA does not have an adequate supply has become significantly more apparent. NIDA has been unable to provide the strains requested for MAPS’ long-delayed Phase 2 clinical trial of smoked marijuana to treat symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans. As a result, the study is proceeding with lower potency marijuana than what MAPS researchers requested.
The DEA has previously claimed that U.S. international treaty obligations under the United Nations Single Convention on Narcotic Drugs (Single Convention) require a federal monopoly, but in April 2016, the State Department released a statement clarifying that the Single Convention does not in fact limit the number of U.S. marijuana producers.
Furthermore, the DEA’s 2009 rejection of the ALJ recommendation to license Craker relied heavily on a U.S. Department of Health and Human Services (HHS) protocol review process, which was eliminated in 2015.
MAPS’ upcoming Phase 2 clinical trial of marijuana for PTSD in veterans is in collaboration with investigators in Phoenix, Arizona, and at Johns Hopkins University, the University of Colorado, and the University of Pennsylvania. The study is funded by a $2.15 million grant to MAPS from the State of Colorado. The study has received full regulatory approval, and will be the first randomized controlled trial of whole plant marijuana as a treatment for PTSD.
Founded in 1986, MAPS is a non-profit research and educational organization working to evaluate the safety and efficacy of botanical marijuana as a potential prescription medicine for specific medical uses approved by the FDA.
- Official Statement from DEA
- 2007 DEA Administrative Law Judge Findings
- 2013 First Circuit Court Decision
- 2015 HHS Statement Ending PHS Protocol Review
- Legal analysis to be submitted in support of Craker’s new application
Additional information can be found at maps.org/research/mmj/dea-license.
Rick Doblin, Ph.D., MAPS Executive Director
Natalie Ginsberg, MAPS Policy & Advocacy Manager
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
This TEDx Talk is titled “Making Peace with Cannabis“. It features Zach Walsh, PhD, who is an Assistant Professor in the UBC Department of Psychology and Co-Director for the Centre for the Advancement of Psychological Science and Law. He is also involved in a current study at UBC which is investigating treating PTSD using Medical Cannabis.
Video is courtesy of the TEDx Talks YouTube channel
The Parents “were putting Cannabinoid Oil on the baby’s pacifier twice a day, increasing the dose… And within two months there was a dramatic reduction”.
“Dr. Courtney pointed out that the success of the Cannabis approach means that “this child, because of that, is not going to have the long-term side effects that would come from a very high dose of chemotherapy or radiation“”.
Video is courtesy of the Lincoln Horsley YouTube channel
Posted by Vincent Banial
A new Research Study out of The Ohio State University found that those who took acetaminophen showed a reduction in empathy. They weren’t as concerned about another person’s person’s hurt feelings. The Study was published on May 05 2016 in the journal “Social Congitive and Affective Neuroscience“, which is one of the Oxford Journals.
Video is courtesy of the Fox Business YouTube channel
Acetaminophen is the main ingredient in the over the counter pain relief medication called Tylenol.
The authors of the study were:
and Jennifer Crocker
Posted by: Vincent Banial
Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.